Zum Inhalt

Solubility-Limited Absorption Identified by a Simplified PBPK Model for the Prediction of Positive Food Effect for BCS II/IV Drugs

  • 03.02.2025
  • Commentary
Erschienen in:

Auszug

Multiple factors in the gut can influence absorption of orally administered drugs. These include gastric emptying, transit in the small intestine, dissolution, solubilization by bile salts, absorption, gut metabolism, and transporter-mediated efflux [1]. Dissolution is also influenced by solubility, drug formulation, and gastric pH, while absorption depends on drug permeability and splanchnic blood flow [2]. Food can influence each of these processes, leading to a positive or negative food effect (FE) through changes in plasma concentration of drugs, thereby impacting the onset and duration of the therapeutic effect [35]. The net impact of food on the absorption of drugs depends on the physiological mechanisms it influences and the solubility/permeability of drugs, according to the biopharmaceutical classification system (BCS) classes of compounds [6] (Fig. 1).
Fig. 1
Impact of food-induced physiological mechanisms for BCS drugs. BCS biopharmaceutical classification system; PPI proton pump inhibitor; GI gastrointestinal; GIT gastrointestinal tract. In column 1, change “Reduce luminal drug concentration leads to increase susceptibility of substrates to intestinal efflux” to “Reduced luminal drug concentration leads to increased susceptibility of substrates to intestinal efflux”. In column 5 change “Increase extent of adsorption proportional to logP (fenofibrate, alectinib, danazol)” to “Increased extent of adsorption proportional to logP (fenofibrate, alectinib, danazol)”. In column 5, change “Increase rate of adsorption (phenytoin)” to “Increased rate of adsorption (phenytoin)”
Bild vergrößern
Titel
Solubility-Limited Absorption Identified by a Simplified PBPK Model for the Prediction of Positive Food Effect for BCS II/IV Drugs
Verfasst von
Karine Rodriguez-Fernandez
José David Gómez-Mantilla
Suneet Shukla
Victor Mangas-Sanjuán
Sheila Annie Peters
Publikationsdatum
03.02.2025
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 3/2025
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-025-01472-w
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.